| Journal of Neuroinflammation | |
| Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF | |
| William A Banks2  Melissa A Fleegal-DeMotta1  Shinya Dohgu3  | |
| [1] Biology Department, Clarke University, Dubuque, IA, USA;Division of Gerontology and Geriatric Medicine, Department of Internal Medicine, University of Washington, Seattle, WA, USA;Division of Geriatric Medicine, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA | |
| 关键词: Mitogen-activated protein kinase; Granulocyte-macrophage colony-stimulating factor; Interleukin-6; Lipopolysaccharide; Human immunodeficiency virus type 1; Blood-brain barrier; | |
| Others : 1212984 DOI : 10.1186/1742-2094-8-167 |
|
| received in 2011-08-18, accepted in 2011-11-30, 发布年份 2011 | |
PDF
|
|
【 摘 要 】
Elevated levels of cytokines/chemokines contribute to increased neuroinvasion of human immunodeficiency virus type 1 (HIV-1). Previous work showed that lipopolysaccharide (LPS), which is present in the plasma of patients with HIV-1, enhanced transcellular transport of HIV-1 across the blood-brain barrier (BBB) through the activation of p38 mitogen-activated protein kinase (MAPK) signaling in brain microvascular endothelial cells (BMECs). Here, we found that LPS (100 μg/mL, 4 hr) selectively increased interleukin (IL)-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) release from BMECs. The enhancement of HIV-1 transport induced by luminal LPS was neutralized by treatment with luminal, but not with abluminal, antibodies to IL-6 and GM-CSF without affecting paracellular permeability as measured by transendothelial electrical resistance (TEER). Luminal, but not abluminal, IL-6 or GM-CSF also increased HIV-1 transport. U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF. These results show that p44/42 and p38 MAPK signaling pathways mediate the LPS-enhanced release of IL-6 and GM-CSF. These cytokines, in turn, act at the luminal surface of the BMEC to enhance the transcellular transport of HIV-1 independently of actions on paracellular permeability.
【 授权许可】
2011 Dohgu et al; licensee BioMed Central Ltd.
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 20150614112254509.pdf | 1211KB | ||
| Figure 7. | 38KB | Image | |
| Figure 6. | 79KB | Image | |
| Figure 5. | 40KB | Image | |
| Figure 4. | 41KB | Image | |
| Figure 3. | 52KB | Image | |
| Figure 2. | 55KB | Image | |
| Figure 1. | 67KB | Image |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
Figure 7.
【 参考文献 】
- [1]Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nature Rev Immunol 2005, 5:69-81.
- [2]McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N: Human immunodeficiency virus-associated dementia: An evolving disease. J Neurovirol 2003, 9:205-221.
- [3]Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Geisslen M: HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. Journal of Infectious Diseases 2010, 202:1768-1769.
- [4]Banks WA, Akerstrom V, Kastin AJ: Adsorptive endocytosis mediates the passage of HIV-1 across the blood-brain barrier: evidence for a post-internalization coreceptor. Journal of Cell Science 1998, 111:533-540.
- [5]Banks WA, Freed EO, Wolf KM, Robinson SM, Franko M, Kumar VB: Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. Journal of Virology 2001, 75:4681-4691.
- [6]Banks WA, Robinson SM, Wolf KM, Bess JW Jr, Arthur LO: Binding, internalization, and membrane incorporation of human immunodeficiency virus-1 at the blood-brain barrier is differentially regulated. Neuroscience 2004, 128:143-153.
- [7]Nakaoke R, Ryerse JS, Niwa M, Banks WA: Human immunodeficiency virus type 1 transport across the in vitro mouse brain endothelial cell monolayer. Experimental Neurology 2005, 193:101-109.
- [8]Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M: A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. The Journal of Immunology 1997, 158:3499-3510.
- [9]Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, et al.: Human immunodeficiency virus type I enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. Journal of Virology 2002, 76:6689-6700.
- [10]Moses AV, Bloom FE, Pauza CD, Nelson JA: Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proceedings of the National Academy of Sciences USA 1993, 90:10474-10478.
- [11]Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA: Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
- [12]Alonso K, Pontiggia P, Medenica R, Rizzo R: Cytokine patterns in adults with AIDS. ImmunolInvest 1997, 26:341-350.
- [13]Gartner S: HIV infection and dementia. Science 2000, 287:602-604.
- [14]Hittinger G, Poggi C, Delbeke E, Profizi N, Lafeuillade A: Correlation between plasma levels of cytokines and HIV-1 RNA copy number in HIV-infected patients. Infection 1998, 26:100-103.
- [15]Fiala M, Looney DJ, Stins M, Way DD, Zhang L, Gan X, Chiappelli F, Schweitzer ES, Shapshak P, Weinand M, et al.: TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Molecular Medicine 1997, 3:553-564.
- [16]Chaudhuri A, Duan F, Morsey B, Persidsky Y, Kanmogne GD: HIV-1 activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of blood-brain barrier dysfunction. J Cereb Blood Flow Metab 2007, 28:697-711.
- [17]Kanmogne GD, Primeaux C, Grammas P: HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permability: implications for the pathogenesis of HIV-associated dementia. Journal of Neuropathology and Experimental Neurology 2005, 64:498-505.
- [18]Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M: HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. Journal of Neuroscience Research 2003, 74:255-265.
- [19]Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, Toborek M: HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Molecular and Cellular Neurosciences 2003, 24:224-237.
- [20]Andras I, Pu H, Tian J, Deli MA, Nath A, Hennig B, Toborek M: Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 2005, 25:1159-1170.
- [21]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV injection. Nature Medicine 2006, 12:1365-1371.
- [22]Blanchard A, Montagnier L, Gougeon ML: Influence of microbial infections on the progression of HIV disease. Trends Microbiol 1997, 5:326-331.
- [23]Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA, Cerami A, Shires GT, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1998, 166:147-153.
- [24]Martich GD, Boujoukos AJ, Suffredini AF: Response of man to endotoxin. Immunobiology 1993, 187:403-416.
- [25]Shalaby MR, Waage A, Aarden L, Espevik T: Endotoxin, tumor necrosis factor-alpha and interleukin-1 induce interleukin 6 production in vivo. Clin Immunol Immunopath 1989, 53:488-498.
- [26]Banks WA, Kastin AJ, Brennan JM, Vallance KL: Adsorptive endocytosis of HIV-1 gp120 by blood-brain barrier is enhanced by lipopolysaccharide. Experimental Neurology 1999, 156:165-171.
- [27]Singh AK, Yiang Y: How does peripheral lipopolysaccharide induce gene expression in the brain of rats? Toxicology 2004, 201:197-207.
- [28]Deli MA, Abraham CR, Kataoka Y, Niwa M: Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cellular and Molecular Neurobiology 2005, 25:59-127.
- [29]Tunkel AR, Rosser SW, Hansen EJ, Scheld WM: Blood-brain barrier alterations in bacterial meningitis: development of an in vitro model and observations on the effects of lipopolysaccharide. In Vitro Cellular & Developmental Biology 1991, 27A:113-120.
- [30]De Vries HE, Blom-Roosemalen MCM, De Boer AG, van Berkel TJ, Breimer DD, Kuiper J: Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. Journal of Pharmacology and Experimental Therapeutics 1996, 277:1418-1423.
- [31]Descamps L, Coisne C, Dehouck B, Cecchelli R, Torpier G: Protective effect of glial cells against lipopolysaccharide-mediated blood-brain barrier injury. Glia 2003, 42:46-58.
- [32]Boveri M, Kinsner A, Berezowski V, Lenfant AM, Draing C, Cecchelli R, Dehouck MP, Hartung T, Prieto P, Bal-Price A: Highly purified lipoteichoic acid from gram-positive bacteria induced in vitro blood-brain barrier disruption through glia activation: role of proinflammatory cytokines and nitric oxide. Neuroscience 2006, 137:1193-1209.
- [33]Veszelka S, Pasztoi M, Farkas AE, Krizbai I, Ngo TK, Niwa M, Abraham CS, Deli MA: Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Nerurochem Int 2007, 50:219-228.
- [34]Verma S, Nakaoke R, Dohgu S, Banks WA: Release of cytokines by brain endothelial cells: a polarized response to lipopolysaccharide. Brain, Behavior, and Immunity 2006, 20:449-455.
- [35]Dohgu S, Banks WA: Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is medited by the p38 mitogen-activated protein kinase pathway. Experimental Neurology 2008, 210:740-749.
- [36]Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, et al.: Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. Journal of Virology 1998, 72:7992-8001.
- [37]Frost EH: Radioactive labelling of viruses: an iodination preserving biological properties. JGenVirol 1977, 35:181-185.
- [38]Montelaro RC, Rueckert RR: On the use of chloramine-T to iodinate specifically the surface proteins of intact enveloped viruses. JGenVirol 1975, 29:127-131.
- [39]Szabo CA, Deli MA, Ngo TKD, Joo F: Production of pure primary rat cerebral endothelial cell culture: a comparison of different methods. Neurobiology 1997, 5:1-16.
- [40]Perriere N, Demeuse P, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud PO, et al.: Puromycin-based purification of rat brain capillary endothelial cell cultures. J Neurochem 2005, 93:279-289.
- [41]Dehouck MP, Jolliet-Riant P, Bree F, Fruchart JC, Cecchelli R, Tillement JP: Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models. J Neurochem 1992, 58:1790-1797.
- [42]Waage A, Bakke O: Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1988, 63:299-302.
- [43]Hoheisel D, Nits T, Franke H, Wegener J, Hakvoort A, Tilling T, Galla HJ: Hydrocortisone reinforces the blood-brain barrier properties in a serum free cell culture system. Biochemical and Biophysical Research Communications 1998, 217:312-315.
- [44]Mayhan WG, Heistad DD: Permeability of blood-brain barrier to various sized molecules. Am J Physiology 1985, 248:H712-H718.
- [45]Chou S, Dix RD: Viral infections and the blood-brain barrier. In Implications of the Blood-Brain Barrier and Its Manipulation, Volume 2: Clinical Aspects. Edited by Neuwelt EA. New York: Plenum Publishing Corporation; 1989:449-468.
- [46]Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, Tsuruo T, Sawada Y, Niwa M, Kataoka Y: Brain pericytes contribute to the upregulation and maintenance of blood-brain barrier functions through transforming growth factor-beta production. Brain Res 2005, 1038:208-215.
- [47]Andjelkovic AV, Zochowski MR, Morgan F, Pachter JS: Qualitative and quantitative analysis of monocyte transendothelial migration by confocal microscopy and three-dimensional image reconstruction. In Vitro Cellular & Developmental BiologyAnimal 2001, 37:111-120.
- [48]de Vries HE, Blom-Roosemalen MCM, van Oosten M, de Boer AG, van Berkel TJC, Breimer DD, Kuiper J: The influence of cytokines on the integrity of the blood-brain barrier. Journal of Neuroimmunology 1996, 64:37-43.
- [49]Farkas G, Marton J, Nagy Z, Mandi Y, Takacs T, Deli MA, Abraham CS: Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6. Neurosci Lett 1998, 242:147-150.
- [50]Dong C, Davis RJ, Flavell RA: MAP kinase in the immune response. Annual Review of Immunology 2002, 20:55-72.
- [51]Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6 cytokine signaling and its regulation. Biochem J 2003, 374:1-20.
- [52]Al-Shami A, Mahanna W, Naccache PH: Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. J Biol Chem 1998, 273:1058-1063.
- [53]Anathbandhu C, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD: STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 2007, 111:2062-2072.
PDF